118 related articles for article (PubMed ID: 3936648)
21. Pyridostigmine counteracts the blunted growth hormone response to growth hormone-releasing hormone of obese children.
Loche S; Pintor C; Cappa M; Ghigo E; Puggioni R; Locatelli V; Müller EE
Acta Endocrinol (Copenh); 1989 May; 120(5):624-8. PubMed ID: 2499149
[TBL] [Abstract][Full Text] [Related]
22. The interaction of human pancreatic growth hormone releasing factor 1-44 with somatostatin in vivo in normal man.
Davies RR; Turner SJ; Orskov H; Johnston DG
Clin Endocrinol (Oxf); 1985 Sep; 23(3):271-6. PubMed ID: 2866855
[TBL] [Abstract][Full Text] [Related]
23. Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men.
Corpas E; Harman SM; Piñeyro MA; Roberson R; Blackman MR
J Clin Endocrinol Metab; 1992 Aug; 75(2):530-5. PubMed ID: 1379256
[TBL] [Abstract][Full Text] [Related]
24. Effect of dietary restriction and repeated growth hormone-releasing factor injections on growth hormone response to growth hormone-releasing factor in obese subjects.
Csizmadi I; Brazeau P; Serri O
Metabolism; 1989 Oct; 38(10):1016-21. PubMed ID: 2507875
[TBL] [Abstract][Full Text] [Related]
25. Effect of withdrawal of somatostatin plus GH-releasing hormone as a stimulus of GH secretion in obesity.
Alvarez P; Isidro L; Leal-Cerro A; Casanueva FF; Dieguez C; Cordido F
Clin Endocrinol (Oxf); 2002 Apr; 56(4):487-92. PubMed ID: 11966741
[TBL] [Abstract][Full Text] [Related]
26. Responses of growth hormone (GH) and somatomedin-C to GH-releasing hormone in healthy aging men.
Pavlov EP; Harman SM; Merriam GR; Gelato MC; Blackman MR
J Clin Endocrinol Metab; 1986 Mar; 62(3):595-600. PubMed ID: 3080468
[TBL] [Abstract][Full Text] [Related]
27. Does growth hormone releasing factor desensitize the somatotroph? Interpretation of responses of growth hormone during and after 10-hour infusion of GRF 1-29 amide in man.
Davis JR; Sheppard MC; Shakespear RA; Lynch SS; Clayton RN
Clin Endocrinol (Oxf); 1986 Feb; 24(2):135-40. PubMed ID: 2871948
[TBL] [Abstract][Full Text] [Related]
28. Blunted growth hormone (GH) responsiveness to GH-releasing hormone in obese patients: influence of prolonged administration of the serotoninergic drug fenfluramine.
Argenio GF; Bernini GP; Sgró M; Vivaldi MS; Del Corso C; Santoni R; Franchi F
Metabolism; 1991 Jul; 40(7):724-7. PubMed ID: 1870427
[TBL] [Abstract][Full Text] [Related]
29. Very-low-calorie diet-induced weight reduction reverses impaired growth hormone secretion response to growth hormone-releasing hormone, arginine, and L-dopa in obesity.
Tanaka K; Inoue S; Numata K; Okazaki H; Nakamura S; Takamura Y
Metabolism; 1990 Sep; 39(9):892-6. PubMed ID: 2118219
[TBL] [Abstract][Full Text] [Related]
30. Short-term met-hGH infusion inhibits somatotroph response to growth hormone releasing hormone (1-44).
Rosenbaum M; Loche S; Balzano S; Gertner JM
Metabolism; 1988 Feb; 37(2):131-5. PubMed ID: 3123873
[TBL] [Abstract][Full Text] [Related]
31. Mechanisms of impaired growth hormone secretion in genetically obese Zucker rats: roles of growth hormone-releasing factor and somatostatin.
Tannenbaum GS; Lapointe M; Gurd W; Finkelstein JA
Endocrinology; 1990 Dec; 127(6):3087-95. PubMed ID: 1979030
[TBL] [Abstract][Full Text] [Related]
32. Growth hormone responsiveness to human pancreatic growth hormone releasing factor in acromegaly: modulatory effects of basal hormone levels and of concomitant somatostatin administration.
Pieters GF; Smals AE; Hermus AR; Smals AG; Benraad TJ; Kloppenborg PW
Clin Endocrinol (Oxf); 1984 Dec; 21(6):701-7. PubMed ID: 6150772
[TBL] [Abstract][Full Text] [Related]
33. Effects of human pancreatic tumor growth hormone-releasing hormone (hpGRH1-44-NH2) on immunoreactive and bioactive plasma growth hormone in normal young men.
Sassolas G; Chatelain P; Cohen R; Boissel JP; Laporte S; Galleyrand J; Claustrat B; Elmcharfi A; Chayvialle JA; Cohen H
J Clin Endocrinol Metab; 1984 Oct; 59(4):705-9. PubMed ID: 6148353
[TBL] [Abstract][Full Text] [Related]
34. Plasma GH and somatomedin C responses to single and repeated administrations of human growth hormone releasing factor (hGRF).
Takano K; Hizuka N; Shizume K; Hirose N; Ling NC
Endocrinol Jpn; 1985 Feb; 32(1):73-80. PubMed ID: 3926476
[TBL] [Abstract][Full Text] [Related]
35. Growth hormone response to growth hormone releasing factor in diabetic men.
Kopelman PG; Mason AC; Noonan K; Monson JP
Clin Endocrinol (Oxf); 1988 Jan; 28(1):33-8. PubMed ID: 3139333
[TBL] [Abstract][Full Text] [Related]
36. Pulsatile growth hormone secretion in normal man during a continuous 24-hour infusion of human growth hormone releasing factor (1-40). Evidence for intermittent somatostatin secretion.
Vance ML; Kaiser DL; Evans WS; Furlanetto R; Vale W; Rivier J; Thorner MO
J Clin Invest; 1985 May; 75(5):1584-90. PubMed ID: 2860126
[TBL] [Abstract][Full Text] [Related]
37. The effect of plasma glucose on the growth hormone response to human pancreatic growth hormone releasing factor in normal subjects.
Sharp PS; Foley K; Chahal P; Kohner EM
Clin Endocrinol (Oxf); 1984 Apr; 20(4):497-501. PubMed ID: 6424979
[TBL] [Abstract][Full Text] [Related]
38. Massive weight loss restores 24-hour growth hormone release profiles and serum insulin-like growth factor-I levels in obese subjects.
Rasmussen MH; Hvidberg A; Juul A; Main KM; Gotfredsen A; Skakkebaek NE; Hilsted J; Skakkebae NE
J Clin Endocrinol Metab; 1995 Apr; 80(4):1407-15. PubMed ID: 7536210
[TBL] [Abstract][Full Text] [Related]
39. Exogenous growth hormone inhibits growth hormone-releasing factor-induced growth hormone secretion in normal men.
Rosenthal SM; Hulse JA; Kaplan SL; Grumbach MM
J Clin Invest; 1986 Jan; 77(1):176-80. PubMed ID: 3080472
[TBL] [Abstract][Full Text] [Related]
40. Long-term administration of acipimox potentiates growth hormone response to growth hormone-releasing hormone by decreasing serum free fatty acid in obesity.
Nam SY; Lee ; Kim KR; Lee HC; Nam MS; Cho JH; Huh KB
Metabolism; 1996 May; 45(5):594-7. PubMed ID: 8622602
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
